PharmiWeb6d
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
Armed robbery in Revesby6d
Solensia 7 Mg/ml Injection Solution for Cats
VMD response to concerns raised following media reports of serious adverse events in cats administered Solensia. The VMD is aware of media reports and ...
Morningstar21d
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse ...
Business Insider21d
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse ...
Le Lézard6d
Quipt Home Medical Responds to Kanen Wealth Management
Quipt Home Medical Corp. (the "Company") , a U.S. based home medical equipment provider, focused on end-to-end respiratory care, acknowledges receipt of a notice from Philotimo Fund, LP, an entity ...
Le Lézard10d
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
In November 2024, the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP ... from Clarity AD for the presence of >4 microhemorrhages and additional ...
BioSpace21d
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions ...
BioSpace21d
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions ...
The Conversation24d
We looked at 54 medicinal cannabis websites to see if they followed the rules. Here’s what we found
But most medicinal cannabis products are not officially approved ... However, we need more stringent monitoring and regulation of how these clinics market themselves. Even if clinics are operating ...